RYAH Medtech partners with SOS Cannabis to provide free legal representation to Canadian patients seeking reimbursement of medical costs.
RYAH Medtech Inc is making it easier for Canadian patients to purchase its dose-measuring dry herb vaporizer by partnering up with SOS Cannabis.
The partnership will provide patients with the opportunity for free legal representation from the team at SOS when seeking reimbursement from government agencies for the costs of purchasing the RYAH vaporizer.
The vaporizer lets patients precisely measure the dose and temperature of their vaporizing sessions and uses HIPAA-compliant medical data to analyze what works for them. RYAH Medtech is a privately-held company based in New York.
WATCH: RYAH Medtech stocks the shelves with its cannabis vaporizer at Maryland dispensary
"As we enter the plant-based medicinal market in Canada with our Health Canada Class I licensed dry-herb cartridges and our dry-herb vaporizer, we will be providing consumers with a complete solution for dose-control, heating, consumption and feedback," RYAH CEO Greg Wagner said.
"The SOS Cannabis partnership takes our solution further by providing patients with the ability to seek reimbursement on RYAH products from governmental agencies, at no additional costs."
SOS Cannabis is a law firm based in Quebec that helps clients seek proactive and retroactive reimbursement for claims made to governmental organizations.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: https://www.proactiveinvestors.com/companies/news/224665/ryah-medtech-partners-with-sos-cannabis-to-provide-free-legal-representation-to-canadian-patients-seeking-reimbursement-of-medical-costs-224665.html
|Printer friendly Cite/link Email Feedback|
|Publication:||Proactive Investors United States|
|Date:||Jul 29, 2019|
|Previous Article:||American Rebel Holdings begins shipping its full-size safes, expands into cannabis safes.|
|Next Article:||Buds & Duds: Cannabis stocks have mixed start to week but Nextleaf shines on addition to OTC markets.|